Varenicline for smoking cessation: a placebo-controlled, randomized study

Area of Science:

• Pharmacology
• Clinical Trials
• Public Health

Background:

• Varenicline tartrate is a selective nicotinic acetylcholine receptor partial agonist designed for smoking cessation.
• This study investigates the efficacy of varenicline in a diverse Asian population.

Purpose of the Study:

• To evaluate the efficacy of a standard varenicline regimen versus placebo for smoking cessation.
• To assess the safety and tolerability of varenicline in smokers from China, Singapore, and Thailand.

Main Methods:

• A 24-week, randomized, double-blind, placebo-controlled trial.
• Participants received varenicline (1 mg twice daily) or placebo for 12 weeks, followed by a 12-week non-treatment follow-up.
• Primary endpoint: 4-week continuous abstinence rate (weeks 9-12). Secondary endpoint: 12-week continuous abstinence rate (weeks 9-24).

Main Results:

• Varenicline significantly increased 4-week continuous abstinence rates (50.3% vs. 31.6%, P=0.0003).
• Continuous abstinence from weeks 9-24 was also significantly higher in the varenicline group (38.2% vs. 25.0%, P=0.0080).
• Treatment effects were consistent across study centers and countries; varenicline was well-tolerated.

Conclusions:

• Varenicline is significantly more effective than placebo for smoking cessation over a 24-week period in Asian smokers.
• The drug demonstrated a favorable safety profile with no significant side-effects noted.